Palvella Therapeutics, Inc. Other Non-Current Assets
Palvella Therapeutics, Inc. (PVLA) had Other Non-Current Assets of $0 as of 2023-12-31, per its 10-K filed 2024-03-29.
Discontinued › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:OtherAssetsNoncurrent · last filed 2024-03-29
- 2023-12-31: Other Assets, Noncurrent $0.00.
- 2023-09-30: Other Assets, Noncurrent $287.00K.
- 2023-06-30: Other Assets, Noncurrent $1.09M.
- 2023-03-31: Other Assets, Noncurrent $1.25M.
| Period end | Other Assets, Noncurrent | Other Assets, Noncurrent as first filed |
|---|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-03-29 | |
| 2023-09-30 | $287.00K 10-Q · filed 2023-11-14 | |
| 2023-06-30 | $1.09M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $1.25M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $1.37M 10-K · filed 2024-03-29 | |
| 2022-09-30 | $1.31M 10-Q · filed 2022-11-04 | |
| 2022-06-30 | $2.36M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $2.67M 10-Q · filed 2022-05-11 | |
| 2021-12-31 | $2.90M 10-K · filed 2023-03-31 | |
| 2021-09-30 | $2.95M 10-Q · filed 2021-11-02 | |
| 2021-06-30 | $3.12M 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $3.21M 10-Q · filed 2021-05-17 | |
| 2020-12-31 | $3.31M 10-K · filed 2022-03-02 | |
| 2020-09-30 | $1.99M 10-Q · filed 2020-11-04 | |
| 2020-06-30 | $1.98M 10-Q · filed 2020-08-10 | |
| 2020-03-31 | $1.89M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $3.15M 10-K · filed 2021-03-31 | |
| 2019-09-30 | $7.77M 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $11.49M 10-Q · filed 2019-08-09 | |
| 2019-03-31 | $1.87M 10-Q · filed 2019-05-10 | |
| 2019-01-01 | $2.03M 10-K · filed 2020-03-13 | |
| 2018-12-31 | $910.00K 10-K · filed 2020-03-13 | |
| 2018-09-30 | $121.00K 10-Q · filed 2018-11-07 | |
| 2018-06-30 | $129.00K 10-Q · filed 2018-08-09 | |
| 2018-03-31 | $130.00K 10-Q · filed 2018-05-10 | |
| 2017-12-31 | $130.00K 10-K · filed 2019-03-18 | |
| 2017-09-30 | $129.27K 10-Q · filed 2017-11-13 | |
| 2017-06-30 | $128.21K 10-Q · filed 2017-08-11 | |
| 2017-03-31 | $126.19K 10-Q · filed 2017-05-15 | |
| 2016-12-31 | $126.00K 10-K · filed 2018-03-15 | $125.74K 10-K · filed 2017-03-30 |
| 2016-09-30 | $127.63K 10-Q · filed 2016-11-10 | |
| 2016-06-30 | $127.34K 10-Q · filed 2016-08-11 | |
| 2016-03-31 | $128.02K 10-Q · filed 2016-05-12 | |
| 2015-12-31 | $126.78K 10-K · filed 2017-03-30 | |
| 2015-09-30 | $97.11K 10-Q · filed 2015-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |